Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-DOTA-FAPI PET/MRI for Malignant Tumors
NCT04554719Unknown
- Start
- May 2020
- Primary completion
- Dec 2023
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Open-label, single-arm trial of 68Ga-FAPI-4 in malignant neoplasm. Primary endpoint: Sensitivity and specificity of 68Ga-DOTA-FAPI PET/MR at 2 years. Status: unknown.
02
Drugs
68Ga-FAPI-4
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT04554719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04554719.